Skip to content

The Application of Music Therapy in Female Amphetamine Use Disorder

The Intervention of Group Therapy: Music in Mood Problems of Female Amphetamine Use Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03221283
Enrollment
40
Registered
2017-07-18
Start date
2017-11-30
Completion date
2018-09-30
Last updated
2018-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphetamine Addiction

Keywords

Music therapy, Depression, Emotion, Motivation

Brief summary

The group music therapy will be used to treat female amphetamine-type stimulant (ATS) addiction

Detailed description

Amphetamine addicts are often accompanied by severe emotional problems and are difficult to control and regulate negative emotions by themselves.And the emotional problems are high risk factors of addicts relapse. Music therapy as the intervention is in order to improve amphetamine addicts' emotional status and the ability of emotion regulation. Self-rating Depression Scale(SDS), Self-rating Anxiety scale(SAS) will be used to investigate the emotion of participants. These methods will also be used to evaluate the efficacy of the intervention.

Interventions

The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.

Sponsors

Shanghai Mental Health Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorder * Junior high school degree or above * Normal vision and hearing * Have emotional problem

Exclusion criteria

* Other substance abuse or dependence in recent a years (except nicotine) * Mental impairment, Intelligence Quotient (IQ) \< 70 * Mental disorders * Physical disease

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline Depression status assessed by Self-rating Depression Scale (SDS) at 4 months.Baseline, 2 months,4 months, and 7monthsevaluate all participants' depression status by Self-rating Depression Scale (SDS)

Secondary

MeasureTime frameDescription
Change from Baseline Craving for ATS assessed by Visual Analog Scales (VAS)Baseline, 2 months,4 months, and 7monthsevaluate all participants' craving for ATS by Visual Analog Scales (VAS)
Empathy ability assessed by Interpersonal Reactivity Index-C(IRI-C)Baseline, 2 months,4 months, and 7monthsevaluate all participants' Empathy ability by Interpersonal Reactivity Index-C(IRI-C)
Anxiety status assessed by Self-rating Anxiety Scale (SAS)Baseline, 2 months,4 months, and 7monthsevaluate all participants' anxiety status by Self-rating Anxiety Scale (SAS)
Change from Baseline emotional status assessed by emotional STROOP paradigmBaseline, 2 months,4 months, and 7monthsevaluate all participants' emotional status by emotional STROOP paradigm
Sleep status assessed by Pittsburgh Sleep Quality Index(PSQI)Baseline, 2 months,4 months, and 7monthsevaluate all participants' sleep status by Pittsburgh Sleep Quality Index(PSQI)
Motivation for treatment assessed by Stages of Change Readiness and Treatment Eagerness Scale(SOCRATES)Baseline, 2 months,4 months, and 7monthsevaluate all participants' motivation for treatment assessed by Stages of Change Readiness and Treatment Eagerness Scale(SOCRATES)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026